Leaderboard Ad

Pediatric Updates in Rhinitis, Rhinosinusitis, and Complicated Sinusitis

Exploring Pediatric Rhinosinusitis: Updates in Management of Rhinitis, Rhinosinusitis, and Complicated Sinusitis

Sunday, October 18, 4:00 – 5:00 pm (ET)

 

Amanda L. Stapleton, MD

In this Panel Presentation, moderated by Patrick C. Walz, MD, of Nationwide Children’s Hospital, with panelists Naweed I. Chowdhury, MD, of Vanderbilt University, David A. Gudis, MD, of Columbia University, and Amanda L. Stapleton, MD, of Children’s Hospital of Pittsburgh, updates in the management of pediatric rhinitis, rhinosinusitis, and complicated sinusitis will be discussed.

With such a vast amount of ground to cover, Dr. Stapleton provided a few highlights for attendees in terms of management updates in each of the three main disease groups.

  1. Pediatric Rhinitis

“Managing pediatric rhinitis can be challenging, particularly in the under 5-year-old population,” said Dr. Stapleton. “There are several new sinonasal topical delivery devices. Some use inhalation techniques to deliver topical medications; some use exhalational techniques. We will review the use and benefits of topical therapy for pediatric rhinitis as well as the role of immunotherapy.”

  1. Pediatric Rhinosinusitis

“We are now realizing that the microbiome of the sinonasal cavity is a diverse environment with complex interactions between the bacteria and viruses that live there,” said Dr. Stapleton. “Children are even more unique than adults, since they have a higher incidence of viral upper respiratory tract infections every year. In the past we assumed that Moraxella, Haemophilus, and Streptococcus pneumoniae were the three most common pathogenic bacteria that cause chronic sinusitis. A recent change in the field has been the use of next-generation sequencing techniques, which allows us to identify changes in the entire microbial community, or microbiome of the sinonasal cavity.”

Understanding how the entire sinonasal microbial community is changing with chronic infection can help physicians to develop appropriate anti-microbial or anti-inflammatory treatment algorithms, she said.

  1. Complicated Sinusitis

“There are several new medical therapies that are helping to change how we manage complicated chronic sinusitis,” said Dr. Stapleton. “New biologic therapy has been approved for adults with CRS with nasal polyps. We will discuss its role in the pediatric population. Also, new triple therapy Cystic Fibrosis transmembrane conductance regulator (CFTR) protein modulators have been approved and are being used in the pediatric Cystic Fibrosis population.” These new medications, said Dr. Stapleton, are changing how physicians can manage these challenging pediatric populations.

 

If you miss this live event, it will become available in the on-demand library of education content within 72 hours following the presentation.

 

Top